U.S. Markets open in 3 hrs 8 mins

Unicycive Therapeutics, Inc. (UNCY)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.6100-0.0200 (-0.76%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.6300
Open2.6350
Bid2.6600 x 900
Ask2.6900 x 900
Day's Range2.5200 - 2.7700
52 Week Range2.3900 - 8.7300
Volume298,923
Avg. Volume1,256,855
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.25
  • PR Newswire

    Unicycive Therapeutics to be Added to Russell Microcap® Index

    Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the Company is scheduled to be added as a member of the Russell Microcap® Index as part of the 2021 Russell indexes reconstitution after the market opens on September 20, 2021, based on a preliminary list of additions.

  • PR Newswire

    Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

  • PR Newswire

    Unicycive Therapeutics Announces Second Quarter 2021 Financial Results

    Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today reported financial results for the second quarter ended June 30, 2021.